Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

1997 • 474 citations

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

2001 • 463 citations

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

2001 • 458 citations

A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.

1995 • 393 citations

Molecular genetics of small cell lung carcinoma

2001 • 378 citations

What is a clinically meaningful change on the Functional Assessment of Cancer Therapy–Lung (FACT-L) Questionnaire?Results from Eastern Cooperative Oncology Group (ECOG) Study 5592

2002 • 373 citations

Clinical significance of ras oncogene activation in human lung cancer

1993 • 361 citations

Twenty Years of Phase III Trials for Patients With Extensive-Stage Small-Cell Lung Cancer: Perceptible Progress

1999 • 351 citations

Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?

2001 • 323 citations

Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules

2000 • 321 citations

Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines

1992 • 298 citations

High frequency of Ki‐ras codon 12 mutations in pancreatic adenocarcinomas

1989 • 295 citations

Topotecan Versus Observation After Cisplatin Plus Etoposide in Extensive-Stage Small-Cell Lung Cancer: E7593—A Phase III Trial of the Eastern Cooperative Oncology Group

2001 • 289 citations

Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer

2000 • 275 citations

[Molecular abnormalities in lung cancer].

2002 • 233 citations

Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer

2003 • 215 citations

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

2003 • 215 citations

Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoB

1997 • 214 citations

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

1998 • 212 citations

Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer

2003 • 200 citations

Phase II study of imatinib in patients with small cell lung cancer.

2003 • 180 citations

Twenty‐five years of clinical research for patients with limited‐stage small cell lung carcinoma in North America

2002 • 171 citations

Phase II and Pharmacodynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Metastatic Pancreatic Adenocarcinoma

2003 • 170 citations

Phase I Clinical and Pharmacologic Study of Chronic Oral Administration of the Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer

2002 • 132 citations

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.

1996 • 132 citations

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

2003 • 125 citations

Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors.

1999 • 105 citations

Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation

2002 • 89 citations

European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.

2003 • 70 citations

Justification for Evaluating New Anticancer Drugs in Selected Untreated Patients With Extensive-Stage Small-Cell Lung Cancer: An Eastern Cooperative Oncology Group Randomized Study

1992 • 42 citations

Cited By (0)

No citing papers found in database